20-F: Kazia Therapeutics Faces Financial Headwinds, Pivots Pipeline

Kazia Therapeutics reported continued net losses and an impairment of its EVT801 asset, while securing new funding and a collaboration for a PD-L1 degrader program.

Summary

• Reported a net loss of A$20.7 million for fiscal year 2025, compared to A$26.8 million in 2024.
• Recognized A$1.6 million in other income from the sale of Cantrixil intellectual property and trademarks to Vivesto AB.
• Incurred a significant impairment loss of A$13.379 million on intangible assets, primarily due to the deprioritization of the EVT801 program.
• Cash and cash equivalents stood at A$4.3 million as of June 30, 2025.
• Raised A$16 million from the sale of American Depositary Shares (ADSs) during fiscal year 2025.
• The FDA indicated that current data from the GBM-AGILE study for Paxalisib is not sufficient to support a New Drug Application (NDA) at this time, recommending additional clinical evidence.
• Entered into an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program (NDL2) in October 2025, with an upfront payment of approximately $1.39 million.
• Received a notification from Nasdaq in May 2025 that its Market Value of Listed Securities (MVLS) was below the minimum $35 million, with 180 days to regain compliance.
• The company has substantial doubt about its ability to continue as a going concern, expecting current funding to last until approximately March 2026.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, a going concern warning, and a major asset impairment. Key pipeline assets have experienced setbacks, with Paxalisib requiring more data for NDA and EVT801 deprioritized. While new collaborations and capital raises provide some positive momentum, the overall financial and operational outlook is highly uncertain and negative.

Positives

• Secured A$1.6 million from the sale of Cantrixil IP and trademarks, providing non-dilutive funding.
• Entered a new exclusive collaboration with QIMR Berghofer for a promising PD-L1 degrader program (NDL2), expanding the pipeline.
• Paxalisib continues in multiple ongoing clinical trials for various brain cancers and metastases, largely funded by third parties.
• Remediated a material weakness in internal control over financial reporting related to the EVT-801 intangible asset acquisition as of June 30, 2024.
• Paxalisib has received multiple FDA designations (Orphan Drug, Fast Track, Rare Pediatric Disease Designation), which can expedite development and review.

Negatives

• Reported a net loss of A$20.7 million for fiscal year 2025 and accumulated losses of A$134.8 million.
• Incurred a significant A$13.379 million impairment loss on intangible assets, primarily due to the deprioritization and write-down of the EVT801 program.
• The FDA determined that current GBM-AGILE study data for Paxalisib is insufficient for a New Drug Application, requiring additional clinical evidence.
• Received a Nasdaq notification for failing to meet the minimum Market Value of Listed Securities ($35 million) and other listing requirements, posing a delisting risk.
• Substantial doubt exists about the company's ability to continue as a going concern, with current funding projected to last only until March 2026.
• Revenue from licensing transactions was significantly lower in FY2025 (A$42k) compared to FY2024 (A$2.3M).

Risks

• Incurred significant net losses since inception and expects to continue incurring losses, potentially never achieving profitability.
• Requires additional funding to operate, which may not be available on acceptable terms or could substantially dilute existing shareholders.
• Product candidates (Paxalisib, EVT801) may fail to show sufficient benefit or encounter profound and unexpected safety concerns in clinical trials.
• Substantial doubt about the ability to continue as a going concern, which may hinder future financing.
• Global economic uncertainty, geopolitical instability, rising inflation, and interest rates could adversely affect business and financial performance.
• May not successfully engage in strategic transactions or new collaborations, impacting product development and cash position.
• Inability to attract and retain qualified key management and technical personnel.
• Potential for future material weaknesses in internal control over financial reporting.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing, leading to potential delays or disruptions.
• Inability to protect intellectual property rights, leading to competition or costly litigation.
• Third-party claims of intellectual property infringement could prevent or delay product development.
• Changes to patent law in the United States and foreign jurisdictions could diminish patent value.
• Limited foreign intellectual property rights may hinder global protection.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Failure to meet Nasdaq continued listing requirements could result in delisting, negatively impacting market price and liquidity.
• The trading price of ADSs is highly volatile, potentially leading to class action litigations.
• Delisting from ASX may adversely affect the price, liquidity, and value of ADSs.
• Reliance on the depository for voting rights and distributions on ADSs.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. investors.
• Loss of foreign private issuer status would require compliance with the Exchange Act's domestic reporting regime, increasing costs.
• Australian takeover laws may discourage takeover offers or significant acquisitions.
• Cybersecurity risks, including intellectual property theft, fraud, and data breaches.
• Inadequate funding for U.S. government agencies (FDA, SEC, NIH) or changes in U.S. policies could hinder operations and regulatory processes.

Future Outlook

The company anticipates completing enrollment for its Paxalisib Phase 1b TNBC trial and expects updated data from the PNOC022 clinical trial for DIPG, as well as preliminary analyses from several investigator-initiated studies in 2025 and 2026. It also plans to commence IND-enabling studies for the new PD-L1 degrader program within six months, aiming for first-in-human studies within approximately 15 months. The company expects its current funding to be sufficient until approximately March 2026 and is actively seeking additional funding sources.

Management Comments

• We are pleased to enter into this agreement with Vivesto, which provides a source of non-dilutive funding that will help advance our proprietary, clinical-stage pipeline.
• Advancing treatment options for hematological cancers is a central focus for Vivesto, and we remain encouraged to see Cantrixil showing clear positive effects as a single agent and in combination with other anti-cancer drugs. The acquisition gives Vivesto full control and allows us to accelerate planning, as well as opportunities to leverage the intrinsic project values and revenues entirely to Vivesto. We are confident Cantrixil can make a significant impact to patients and build shareholder value.
• Following discussion with the U.S. Food and Drug Administration (FDA) in December 2024 to review the GBM-AGILE results, the FDA indicated that the current data are not sufficient to support a new drug application (NDA) at this time and recommended that additional clinical evidence be obtained to further characterize Paxalisib's efficacy and safety in this population.

Industry Context

The oncology drug development industry is highly competitive and capital-intensive. Kazia's pivot from ovarian cancer for Cantrixil and deprioritization of EVT801, alongside the pursuit of a PD-L1 degrader, reflects a dynamic landscape where companies must adapt to clinical trial outcomes and market potential. The ongoing need for capital, coupled with the FDA's stringent requirements for NDA approval, highlights the significant challenges faced by smaller biotechnology firms in bringing novel therapies to market. The focus on PI3K pathway mutations and immune modulation aligns with broader industry trends towards precision medicine and combination immunotherapies in cancer treatment.

Comparison to Industry Standards

• The FDA's determination that Paxalisib's GBM-AGILE data is insufficient for an NDA is a significant setback, as many oncology drug candidates fail to meet the high bar for regulatory approval, often requiring additional, costly trials.
• The 100% overall response rate in 9 evaluable patients from the MSKCC Phase I study for Paxalisib in brain metastases is an encouraging early signal, but Phase I data is preliminary and often does not translate to later-stage success, which is a common challenge in drug development.
• The deprioritization and impairment of EVT801, despite positive Phase I data, is not uncommon in the industry where companies must make strategic decisions to focus limited resources on programs with the highest perceived likelihood of success and commercial potential.
• The acquisition of a PD-L1 degrader program aligns with the industry's strong interest in novel immunotherapies, particularly those that can overcome resistance mechanisms in established checkpoint blockade treatments.
• The company's continuous reliance on equity financing and its "going concern" warning are typical for early-stage biotechnology companies with no commercialized products, but the Nasdaq delisting risk adds an extra layer of concern compared to more stable industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• No proceedings exist as of June 30, 2025, that would have a material adverse effect on the financial position.

Related Party Transactions

• John Friend was reimbursed for travel and accommodation expenses of $107,932. No other transactions or loans with related parties were entered into during fiscal years 2023, 2024, and 2025, or up to the date of the report.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises, potential loss of investment due to "going concern" doubt, and reduced liquidity/value if Nasdaq delisting occurs. The ADS ratio changes also impact their holdings.
• Employees: The company's financial instability and strategic shifts could create uncertainty regarding job security and future growth opportunities.
• Customers/Patients: Development delays for Paxalisib and deprioritization of EVT801 could impact the availability of potential new treatments. New PD-L1 degrader program offers future hope.
• Creditors: Face risk due to the company's "going concern" warning and limited cash resources.
• Suppliers/Partners: May face risks related to the company's financial stability and ability to meet contractual obligations, though new collaborations indicate continued engagement.

Next Steps

• Evaluate FDA recommendations and potential next steps for Paxalisib, including designing future clinical studies and regulatory pathways.
• Continue enrollment in the LUMOS2 Phase II study for IDH mutant gliomas.
• Provide an update on the Weill Cornell Medicine Phase II study in GBM in 2025.
• Continue enrollment in the DFCI Phase II study for PCNSL.
• Present further analyses and updates from the PNOC022 study in 2025.
• Continue enrollment in the OPTIMISE Phase II study for advanced solid tumors in children.
• Complete final analyses and anticipate clinical study reports for MSKCC Phase I and DFCI Phase II (HER2+ breast cancer brain metastases) in 2026.
• Complete enrollment in the company-sponsored Phase 1b clinical trial for Paxalisib in TNBC, anticipated in 2026.
• Publish preliminary analyses from expanded-access clinical experience with Paxalisib in TNBC.
• Commence IND-enabling studies for the PD-L1 degrader program within six months, aiming for first-in-human studies within approximately 15 months.
• Actively monitor MVLS and take measures to regain compliance with Nasdaq listing requirements by November 10, 2025.
• Explore regional and strategic partnerships for EVT801.
• Seek additional funding sources, including equity and debt financings, strategic alliances, and business development.

Key Dates

Recommendation

Kazia Therapeutics faces severe financial distress, evidenced by recurring net losses, substantial accumulated losses, and a 'going concern' warning from its auditors. The FDA's determination that Paxalisib's GBM-AGILE data is insufficient for an NDA is a major setback for its lead asset, requiring further costly clinical development. The deprioritization and significant impairment of the EVT801 program further highlight pipeline challenges. Additionally, the company is at risk of delisting from Nasdaq due to non-compliance with listing standards, which would severely impact liquidity and investor confidence. While new collaborations and capital raises provide temporary relief, they also contribute to significant shareholder dilution and do not fundamentally address the underlying financial instability and clinical development hurdles. Given these compounding negative factors, a 'strong sell' recommendation is warranted for investors.

Keywords

Oncology, Biotechnology, Drug Development, Paxalisib, Glioblastoma, Brain Cancer, EVT801, VEGFR3 Inhibitor, Cantrixil, PD-L1 Degrader, Clinical Trials, SEC Filing, NASDAQ, Financial Losses, Intellectual Property, Capital Raise, Going Concern, Orphan Drug, Fast Track Designation, Rare Pediatric Disease Designation